Alphatec Holdings, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 5, 2026 at 3:30 PM GMT+3 3 min read

Alphatec Holdings, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance was driven by a 'compounding engine' where 24% growth in new surgeon adoption and 20% procedural volume growth fueled a 15% revenue increase.
Management attributes the 17% surgical revenue growth to a shift from selling individual 'widgets' to architecting entire procedures, particularly in lateral surgery.
The EOS imaging platform serves as a critical 'hunting license,' providing access to prestigious academic institutions and fellowship programs that were previously inaccessible.
Profitability expansion was achieved through disciplined resource allocation and a 260-basis-point improvement in gross margins, driven by inventory efficiency and supply chain volume leverage.
The company is successfully replicating its clinical distinction model in high-value international markets like Japan and Australia, which is beginning to contribute meaningfully to the top line.
Management highlighted that 32% revenue lift per surgeon is observed within six months of EOS Insight adoption, validating the informatics platform as a driver of implant pull-through.

Outlook and Strategic Initiatives

Full-year surgical revenue guidance remains at $805 million, implying an acceleration to 18% growth in the second half of 2026.
Adjusted EBITDA guidance was raised to $140 million (16% margin) based on sustained gross margin improvements and operating discipline.
Management expects high-teens surgical case volume growth in the second half, supported by front-loaded investments of $66 million in inventory and instrument sets.
Free cash flow is projected to reach $4 million to $6 million in Q3, stepping up significantly in Q4 as capital expenditure on instrument sets moderates.
The long-term strategy focuses on converting the EOS data moat into predictive analytics for surgical planning, aiming for $1 billion in revenue by 2027.

Operational Context and Risk Factors

Revenue per case declined 2.7% year-over-year, primarily due to stabilized but lower-than-expected biologics attachment and international mix headwinds.
A new capital structure with JPMorgan and TD Cowen consolidated legacy facilities, extending maturities to 2031 and reducing annual interest expense by over $6 million.
Biologics attachment remains a focused area for execution; management plans to address this through sales discipline and the future launch of a BMP product via the Theradaptive partnership.
Management noted that EOS installations can be 'bumpy' quarter-to-quarter due to facility space requirements and complex installation dynamics rather than lack of demand.

Q&A Session Highlights

Drivers of sales force productivity and SG&A leverage

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management sees significant remaining opportunity in converting TLIF procedures to lateral and expanding their footprint in the deformity market.
Profitability is scaling through a 45% drop-through of revenue growth to EBITDA, supported by improved inventory 'chain of custody' and supply chain efficiencies.

Factors behind the revised revenue per procedure outlook

The shift to 'low single digit' decline (from flattish) is mostly due to biologics attachment stabilizing at lower levels rather than improving as quickly as originally forecasted.
Management removed aggressive second-half improvement assumptions for biologics to reflect current performance levels, though comps become easier in Q4.

Impact of recent ACA changes on procedure volumes

Management stated that ATEC has less than 5% exposure to ACA-related volumes, making it a non-factor for their growth trajectory.
Spine surgery for neural pain is viewed as non-elective, leading to robust and consistent volume despite macro concerns in the broader ortho market.

Adoption trends among new surgeon users

A younger cohort of surgeons is increasingly entering the ATEC ecosystem through cervical procedures before graduating to more complex lateral and deformity cases.
EOS Insight acts as the initial impetus for these younger surgeons, who are more inclined toward data-driven, alignment-based surgical planning.